Health Center

1. NuvaRing Lawsuit: Judge Requires Disclosure of Psychiatric History ...
The first Case Management Order was issued by the Court on November 7, 2008, requiring that any Plaintiffs who have filed a NuvaRing lawsuit in the MDL by that date, must complete a Plaintiff Fact Sheet prior to February 6, 2009. ...

2. Concerns About Byetta Deaths Lead Amylin to Cut Work Force ...
In fact patients on Byetta have LOWER incidents of pancreatitus. Ever see the aspirin FDA event sheet where thousands die yearly? This is hype. the 6 SIX were alcoholics etc ,the drug is amazingly safe.Amylin cut backs are due to the ...

3. lizards save my life
a b c "gila monster fact sheet". smithsonian national zoological park. retrieved on 2008-06-06. ^ a b c wilson, don w.; burnie, david (2001). animal. london: dk, 419. isbn 0-7894-7764-5. ^ "meet our animals: gila monster". ...

4. Weekly Medical News Newsletter - 1 September 2008
Fact Sheet Examines 2006 Massachusetts Health Care Reform Law; Study Finds More Consumers Seeking Health Care Information Online, 25 Aug 2008. Kaiser Daily Health Policy Report Feature Highlights Recent Blog Entries, 25 Aug 2008 ...

5. Diabetes Drug Spending Rising on RxList
Find out more about why spending on diabetes drugs, such as Byetta and Januvia, has steadily increased over the last few years.

6. Gadolinium Lawyers Set to Meet with Court about Product ...
At a status conference before Judge Polster on September 24, 2008, the Court indicated that the plaintiffs’ lawyers will need to provide product identification in 75% of the cases where a plaintiff fact sheet has been exchanged before ...

7. Byetta - PCOS Message Board
The lady gave my mom in law the diet and Byetta information sheet. If anyone is interested in the diet, let me know and I can type it out and email it to you. Or I might even post it on here. Thanks! ...

8. Which is better for diabetes, Byetta or Januvia?
This information reflects FDA’s current analysis of data available to FDA concerning this drug. FDA is not advising practitioners to discontinue prescribing the product. FDA intends to update this sheet when additional information or ...

9. The IN VIVO Blog: The Case for Byetta LAR (Part 2)
But Byetta LAR is not a case of asking FDA to approve a new agent to lower blood sugar, but rather a case of asking FDA to approve an improved version of an already marketed drug. And, in fact, of a drug that has an attractive ...

10. The IN VIVO Blog: Miscommunicating Risk (Part 2): The Byetta...
I know FDA is at least aware of that fact and trying different ways to adjust to that reality. Based on Byetta, I'm not convinced sponsors or investors are at that point yet. 8/28/08 8:05 AM; Anonymous said... Dear Michael, ...